DOI: 10.18413/2313-8955-2016-2-1-17-23

XANTHINE METABOLISM IN THE PROGRESSION OF CHRONIC HEART FAILURE: FEATURES OF DISORDERS IN PATIENTS WITH CONCOMITANT CHRONIC KIDNEY DISEASE

Maryna V. Kolomiiets
Alexander V. Bilchenko

The article presents some data of the xanthine metabolism violations study in patients with chronic heart failure and concomitant chronic kidney disease at different stages. The study demonstrates a significant increase in xanthine oxidase activity, that confirms changes of metabolism towards oxidase pathway of uric acid in patients with chronic heart failure with concomitant chronic kidney disease. The negative impact of xanthine metabolism violations on the clinical course and progression of heart failure functional class was demonstrated. Thus in patients with CHF and CKD the progression of functional class and decrease in the left ventricular ejection fraction was associated with increased xanthine oxidase activity, while in patients without concomitant CKD it was associated only with increased serum uric acid levels. The obtained results also show the important role of xanthine oxidase system in the impaired kidney function.

Keywords: xanthine oxidase, chronic heart failure, chronic kidney disease, hyperuricemia.

Number of views: 5884 (view statistics)

Количество скачиваний: 7150

Full text (HTML)Full text (PDF)To articles list

Information for citation:

Kolomiets MV, Bilchenko AV. Xanthine metabolism in the progression of chronic heart failure: features of disorders in patients with concomitant chronic kidney disease. Research Result. Medicine and Pharmacy Series. 2016;2(1):17-23 (In Russian). DOI: 10.18413/2313-8955-2016-2-1-17-23

User comments
Reference lists

While nobody left any comments to this publication.
You can be first.

Doehner W. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options // Semin Nephrol. 2011. №31(5). Pp. 433–440;
Filiopoulos V. New insights into uric acid effects on the progression and prognosis of chronic kidney disease // Ren Fail. 2012. № 34(4). Pp. 510–520;
Filippatos G.S. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data / G.S. Filippatos, M.I. Ahmed, J.D. Gladden [et al.] // Eur. Heart. J. 2011. № 32(6). Pp. 712–720;
Goicoechea M. Allopurinol and Progression of CKD and Cardiovascular Events: Long-term Follow-up of a Randomized Clinical Trial / M. Goicoechea, S. Garcia de Vinuesa, U. Verdalles [et al.] // Am J Kidney Dis. 2015. № 65(4). Pp. 543–549;
Huang H. Uric acid and risk of heart failure: a systematic review and meta-analysis / H. Huang, B. Huang, Y. Li [et al.] // Eur J Heart Fail. 2014. Jan;16(1). Pp. 15–24;
Johnson R.J. Uric acid and chronic kidney disease: which is chasing which? / R.J. Johnson, T. Nakagawa, D. Jalal [et al.] // Nephrol Dial Transplant. 2013. Sep;28(9). Pp. 2221-2228;
Kaufman M. Uric acid in heart failure: a biomarker or therapeutic target? // Heart Fail Rev. 2013. Mar;18(2). Pp. 177-186;
Madero M. Uric acid and long-term outcomes in CKD / M. Madero, M.J. Sarnak, X. Wang [et al.] // Am J Kidney Dis. 2009. №53(5). Pp. 796–803;
Nashar K. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? // Adv Chronic Kidney Dis. 2012. Nov;19(6). Pp. 386-391;
Neri L. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider / L. Neri, L.A. Rocca Rey, K.L. Lentine [et al.] // Am J Kidney Dis. 2011. Sep; 58(3). Pp. 398–408;
Sturm G. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? (The Mild to Moderate Kidney Disease (MMKD) Study) / G. Sturm, B. Kollerits, U. Neyer [et al.] // Exp Gerontol. 2008. № 43(4). Pp. 347–352;
Vaduganathan M. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial) / M. Vaduganathan, S.J. Greene, A.P. Ambrosy [et al.] // Am J Cardiol. 2014. Dec 1; 114 (11).- Pp. 1713-1721.

All journals

Send article

Research Results in Biomedicine is included in the scientific database of the RINTs (license agreement No. 765-12/2014 dated 08.12.2014).

The journal is included in the list of peer-reviewed scientific publications recommended by the Higher Attestation Commission

The journal is indexed by the following scientific databases and platforms

Research Results in Biomedicine (ISSN 2658-6533)

The journal materials and website are licensed under Creative Commons «Attribution» 4.0 International.

The Founder: Federal State Autonomous Educational Institution of Higher Education "Belgorod National Research University"The Founder’s address: 85 Pobedy Street, Belgorod, the Belgorod region, 308015, Russia

The Publisher: Federal State Autonomous Educational Institution of HigherEducation "Belgorod National Research University" The Founder’s address:85 Pobedy Street, Belgorod, the Belgorod region, 308015, Russia

Editors Office: chief editor Mikhail I. Churnosov, e-mail: RR_MedPharm@bsuedu.ru, phone: +7 (4722) 30-14-03.

Regulations on the Journal

Certificate

Have questions?
You can write to us:

✉ Executive Secretary

✉ Site administration

✉ Content manager